To validate the benefit of anti-ERK5 therapy in the context of treatment-resistant HER2+ breast cancers, we performed detailed comparative analyses of breast cancer cell sensitivity to JWG-045, lapatinib or combined treatment. The gene discussed is ERBB2; the disease is breast cancer.